

From: Prasad, Dr Krishna
Sent: 25 March 2022 16:52
To: PHARMACO - Pirmohamed, Dr M (i); Bonnerjea, Julian
Cc: [REDACTED]
Subject: RE: Request for Written Comments - [REDACTED]
[REDACTED]
[REDACTED] Deadline 08/04/2022

Thanks Munir,
Yes - intention is to discuss at the EWG. [REDACTED] has put them together at short notice. He is away I think next week as are others. So this is more a preparatory step.

Krish

From: Pirmohamed, Munir <munirp@liverpool.ac.uk>
Sent: 25 March 2022 16:39
To: Bonnerjea, Julian <Julian.Bonnerjea@mhra.gov.uk>; Prasad, Dr Krishna <Krishna.Prasad@mhra.gov.uk>
Cc: [REDACTED]
Subject: FW: Request for Written Comments - [REDACTED]
[REDACTED] Deadline 08/04/2022
Importance: High

Why aren't we discussing this at the committee, rather than relying on written comments.

Munir

Professor Sir Munir Pirmohamed, MB ChB (Hons), PhD, FRCP, FRCP(E), FFPM, FRSB, FBPhS, FMedSci
David Weatherall Chair of Medicine and NHS Chair of Pharmacogenetics
Director, Centre for Drug Safety Science and Wolfson Centre for Personalised Medicine
Director, HDR UK North
Institute of Systems, Molecular and Integrative Biology (ISMIB)
University of Liverpool
Block A: Waterhouse Building
1-5 Brownlow Street
Liverpool L69 3GL

T +44 151 794 5549
F +44 151 794 5059
E munirp@liverpool.ac.uk

PA: [REDACTED]

From: Expert Committee Support (ECS) <expertcommittee@mhra.gov.uk>

Sent: 25 March 2022 15:47

To: Dr Andrew Riordan [REDACTED] Dr Robin Thorpe

[REDACTED]
CHM - Misbah, Dr Siraj [REDACTED]; CPSEAG - Lowe, Robert

[REDACTED]
CPSEAG - V'lain Fenton-May [REDACTED]; Mrs Madeleine Wang

[REDACTED]; Ms Susan Hunneyball [REDACTED]

Professor

Chris Robertson [REDACTED]; CTBVEAG - Weir, Dr Christopher J

[REDACTED] Professor David Goldblatt [REDACTED]

Prof Gordon Dougan

[REDACTED] CTBVEAG - Lachmann, Dr Helen [REDACTED]; Prof

Judith

Breuer [REDACTED]; CHM - Kevin Taylor [REDACTED]

Professor Kimme Hyrich

[REDACTED]; Professor Marc Turner [REDACTED];

French, Neil

[french] Prof [REDACTED]; Professor Paul Lehner [REDACTED];

PMEAG - Price,

Shirley [REDACTED] Pirmohamed, Munir <munirp@liverpool.ac.uk>; [REDACTED]

[REDACTED]

[REDACTED] Solomon, Tom [REDACTED] [REDACTED]

[REDACTED]

[REDACTED] CPS - Perrie, Yvonne

[REDACTED]; Sir Michael

Jacobs [REDACTED]; [REDACTED]

Cc: Expert Committee Support (ECS) <expertcommittee@mhra.gov.uk>; [REDACTED]

[REDACTED] Bonnerjea, Julian <Julian.Bonnerjea@mhra.gov.uk>;

Prasad, Dr

Krishna <Krishna.Prasad@mhra.gov.uk>

Subject: Request for Written Comments - [REDACTED]

[REDACTED]

Deadline 08/04/2022

Importance: High

OFFICIAL - SENSITIVE COMMERCIAL, NOT FOR PUBLICATION

Dear Chair & Members,

[REDACTED]

[REDACTED]

This issue is put before the VBREWG for awareness: comments on significance of this as a safety concern are invited by 8 April.

The following has been uploaded for you in the COVID-19 VBR+Experts (CPS-CTBV) > Written Comments folder on Intralinks:

* [REDACTED]

It is primarily for information but comments are welcome to develop the position of the MHRA on this topic. Please could any comments be provided by COB on Friday 8th April.

Link to Intralinks: [REDACTED]

Confidentiality

The paperwork and any other correspondence are strictly confidential, and must not be disclosed. All paperwork has been dispatched via a secure electronic channel. Please note that such paperwork must remain confidential at all times.

We look forward to hearing from you. Many thanks in advance.

Kind regards,

[REDACTED]
Regulatory, Scientific & Business Support Unit (RSBU), Licensing Division

Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU.

[REDACTED]

DISCLAIMER This email and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this email is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming

and outgoing email messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications. For more information on the Department of Health's email policy, click [DHTermsAndConditions](#)